Merck Report Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 Trial as Adjuvant Treatment for Renal Cell Carcinoma

 Merck Report Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 Trial as Adjuvant Treatment for Renal Cell Carcinoma

Merck Report Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 Trial as Adjuvant Treatment for Renal Cell Carcinoma

Shots:

  • The P-III KEYNOTE-564 trial involves assessing Keytruda (200 mg, IV, on day1 of each 3wks. cycle for up to 17 cycles) as adjuvant therapy vs PBO in 950 patients with RCC, following nephrectomy and resection of metastatic lesions
  • The study showed improvement in 1EPs i.e DFS while the trial will continue to evaluate its 2EPs i.e. OS. The safety profile was consistent with observed in previously reported studies
  • Keytruda is currently approved in the US, EU and Japan in combination with axitinib as a 1L treatment for advanced RCC. The company continues to evaluate the therapy for other cancer treatments across multiple settings and stages of RCC through its broad clinical program

Click here to­ read full press release/ article | Ref: Merck | Image: Pittsburgh Post-Gazette

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post